section name header

Information

[Section Outline]

Definition !!navigator!!

PsA is a chronic inflammatory arthritis that affects up to 30% of persons with psoriasis. HLA-B27 is found in 50-70% with axial disease but <20% of pts with only peripheral involvement. Onset of psoriasis usually precedes development of joint disease; approximately 15-20% of pts develop arthritis prior to onset of skin disease. Nail changes occur in most pts with PsA, dactylitis and enthesitis are common in PsA and help to distinguish it from other joint disorders.

Patterns of Joint Involvement !!navigator!!

There are five patterns of joint involvement in PsA, which can overlap:

  • Asymmetric oligoarthritis: often involves distal interphalangeal/proximal interphalangeal (DIP/PIP) joints of hands and feet, knees, wrists, ankles.
  • Symmetric polyarthritis (40%): resembles rheumatoid arthritis except rheumatoid factor is negative, absence of rheumatoid nodules.
  • Predominantly DIP joint involvement (15%): high frequency of association with psoriatic nail changes.
  • “Arthritis mutilans” (3-5%): aggressive, destructive form of arthritis with severe joint deformities and bony dissolution.
  • Spondylitis and/or sacroiliitis: axial involvement is present in 20-40% of pts with psoriatic arthritis; may occur in absence of peripheral arthritis.

Evaluation !!navigator!!

  • Negative tests for rheumatoid factor.
  • Anemia, elevated ESR.
  • HIV infection should be suspected in fulminant disease.
  • Inflammatory synovial fluid and biopsy without specific findings.
  • Radiographic features include erosion at joint margin, bony ankylosis, tuft resorption of terminal phalanges, “pencil-in-cup” deformity (bone proliferation at base of distal phalanx with tapering of proximal phalanx), axial skeleton with asymmetric sacroiliitis, asymmetric nonmarginal syndesmophytes.
TREATMENT

Psoriatic Arthritis

  • Coordinated therapy is directed at the skin and joints.
  • Pt education, physical and occupational therapy.
  • TNF modulatory agents (etanercept, infliximab, adalimumab, golimumab, certolizumab pegol) can improve joint disease and delay radiographic progression. Etanercept, infliximab, and certolizumab pegol can also be used for skin disease. Infliximab biosimilar can be used for skin and joint disease.
  • Ustekinumab (anti-IL-12/23 p40 monoclonal antibody) has efficacy for both skin and joint disease.
  • Apremilast (phosphodiesterase 4 inhibitor) benefit skin and joint involvement.
  • Secukinumab and ixekizumab, (IL-17A antagonists), have been found to improve disease activity and can also be used for moderate to severe plaque psoriasis.
  • Abatacept (CTLA4-Ig) has been used to reduce signs and symptoms of active PsA.
  • Tofacitinib (Janus kinase inhibitor) used in adults with active PsA who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
  • NSAIDs.
  • Intraarticular steroid injections-useful in some settings. Systemic glucocorticoids should rarely be used as may induce rebound flare of skin disease upon tapering.
  • Sulfasalazine 2-3 g/d has clinical efficacy but does not halt joint erosion.
  • Methotrexate 15 mg/week may not be disease modifying but it may have symptom-modifying effects and can improve skin scores.
  • Leflunomide may be of benefit for skin and joint disease.

Outline

Section 12. Allergy, Clinical Immunology, and Rheumatology